Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.580
+0.010 (0.22%)
Mar 9, 2026, 2:42 PM EDT - Market open
Taysha Gene Therapies Employees
Taysha Gene Therapies had 73 employees as of December 31, 2024. The number of employees increased by 21 or 40.38% compared to the previous year.
Employees
73
Change (1Y)
21
Growth (1Y)
40.38%
Revenue / Employee
$86,438
Profits / Employee
-$1,368,890
Market Cap
1.25B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 73 | 21 | 40.38% |
| Dec 31, 2023 | 52 | -13 | -20.00% |
| Dec 31, 2022 | 65 | -113 | -63.48% |
| Dec 31, 2021 | 178 | 140 | 368.42% |
| Dec 31, 2020 | 38 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 165 |
| Precigen | 143 |
| MoonLake Immunotherapeutics | 130 |
| Zenas BioPharma | 130 |
| DBV Technologies | 117 |
| Savara | 59 |
| AtaiBeckley | 54 |
TSHA News
- 3 days ago - Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 2 months ago - Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome - GlobeNewsWire
- 4 months ago - Taysha Gene Therapies, Inc. (TSHA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4 - GlobeNewsWire
- 5 months ago - Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome - GlobeNewsWire
- 5 months ago - Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting - GlobeNewsWire